Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Jan;17(1):8-9.
doi: 10.1038/mt.2008.275.

Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication

Manish K Aghi  1 , E Antonio Chiocca
Affiliations
Comment

Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication

Manish K Aghi et al. Mol Ther. 2009 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA.Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 2007254722–4729.et al - PubMed
    1. Stupp R, van den Bent MJ., and , Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5:198–206. - PubMed
    1. Aghi M, Visted T, Depinho RA., and , Chiocca EA. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene. 2008;27:4249–4254. - PMC - PubMed
    1. Smith KD, Mezhir JJ, Bickenbach K, Veerapong J, Charron J, Posner MC.Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1 J Virol 2006801110–1120.et al - PMC - PubMed
    1. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F.A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting Mol Ther 200410958–966.et al - PubMed